Zobrazeno 1 - 10 of 10 pro vyhledávání: '"Masahiko Fushimi"'
1
Comparison of inulin clearance with 2-h creatinine clearance in Japanese pediatric patients with renal disease: open-label phase 3 study of inulin
Autor: Takafumi Sano, Naoya Fujita, Masaki Yamamoto, Kazumoto Iijima, Koichi Kamei, Masahiko Fushimi, Riku Hamada, Kenji Ishikura, Tomoyuki Sakai, Yoshimitsu Gotoh, Osamu Uemura
Publikováno v: Clinical and Experimental Nephrology
Background There is no approved dosage and administration of inulin for children. Therefore, we measured inulin clearance (Cin) in pediatric patients with renal disease using the pediatric dosage and administration formulated by the Japanese Society
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a4f852e8696cfa5a4fe05ea5418700a4
http://europepmc.org/articles/PMC8770449
Zobrazit plný text záznamu
2
Ideal pharmacokinetic profile of dotinurad as a selective urate reabsorption inhibitor
Autor: Junichiro Uda, Tomomitsu Sasaki, Seiichi Kobashi, Takashi Iwanaga, Masahiko Fushimi, Tetsuo Ohashi, Azusa Ito, Kengo Miyata, Koichi Omura
Publikováno v: Drug Metabolism and Pharmacokinetics. 35:313-320
Dotinurad, a novel selective urate reabsorption inhibitor (SURI), has potent inhibitory effects at low doses on the uptake of urate by urate transporter 1 (URAT1, solute carrier family 22 member 12 [SLC22A12]), localized at the apical membrane of ren
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0997f6717f192b86434b9b73b894e0ea
https://doi.org/10.1016/j.dmpk.2020.03.002
Zobrazit plný text záznamu
3
Dotinurad versus benzbromarone in Japanese hyperuricemic patient with or without gout: a randomized, double-blind, parallel-group, phase 3 study
Autor: Takafumi Sano, Tatsuo Hosoya, Tomomitsu Sasaki, Masahiko Fushimi, Tetsuo Ohashi
Publikováno v: Clinical and Experimental Nephrology
Background Dotinurad is a novel selective urate reabsorption inhibitor that reduces serum urate levels in hyperuricemic patients with or without gout by selectively inhibiting urate transporter 1. This study was conducted to compare the efficacy and
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::69aa91e39125d06c20e92126eea5fd19
https://doi.org/10.1007/s10157-020-01849-0
Zobrazit plný text záznamu
4
Clinical pharmacological study of dotinurad administered to male and female elderly or young subjects
Autor: Daisuke Okui, Masahiko Fushimi, Hiroshi Nakatani, Tetsuo Ohashi, Tomomitsu Sasaki
Publikováno v: Clinical and Experimental Nephrology
Background Dotinurad is a novel selective urate reabsorption inhibitor (SURI) that selectively inhibits the reabsorption of uric acid in renal tubules and promotes the excretion of uric acid into urine. In this study, the effects of age and gender on
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8309164567c2400e21cf08f7a3a85d13
https://doi.org/10.1007/s10157-019-01836-0
Zobrazit plný text záznamu
5
Effects of mild and moderate renal dysfunction on pharmacokinetics, pharmacodynamics, and safety of dotinurad: a novel selective urate reabsorption inhibitor
Autor: Tatsuo Hosoya, Tomomitsu Sasaki, Hiroyuki Fukase, Masahiko Fushimi, Daisuke Okui, Tetsuo Ohashi
Publikováno v: Clinical and Experimental Nephrology
Background Dotinurad, a novel selective urate reabsorption inhibitor, exerts a serum uric acid-lowering effect by selectively inhibiting urate transporter 1 (URAT1) in patients with hyperuricemia. It is generally known that the progression of renal d
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b521859fb7fb347ebc11ad51f797842
https://doi.org/10.1007/s10157-019-01825-3
Zobrazit plný text záznamu
6
Clinical efficacy and safety of dotinurad, a novel selective urate reabsorption inhibitor, in Japanese hyperuricemic patients with or without gout: randomized, multicenter, double-blind, placebo-controlled, parallel-group, confirmatory phase 2 study
Autor: Tomomitsu Sasaki, Masahiko Fushimi, Tetsuo Ohashi, Tatsuo Hosoya, Takafumi Sano
Publikováno v: Clinical and Experimental Nephrology
Background Dotinurad, a novel selective urate reabsorption inhibitor (SURI), reduces serum uric acid levels by selectively inhibiting urate transporter 1 (URAT1) for the treatment of hyperuricemia with or without gout. We confirmed the serum uric aci
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4bf0d8aeda5831be4902b60d5e981962
https://doi.org/10.1007/s10157-019-01818-2
Zobrazit plný text záznamu
7
The effect for hyperuricemia inpatient of uric acid overproduction type or in combination with topiroxostat on the pharmacokinetics, pharmacodynamics and safety of dotinurad, a selective urate reabsorption inhibitor
Autor: Daisuke Okui, Tomomitsu Sasaki, Masahiko Fushimi, Tetsuo Ohashi
Publikováno v: Clinical and Experimental Nephrology
Background Dotinurad, a novel selective urate reabsorption inhibitor (SURI), increases urinary uric acid excretion. The aim of this study is to examine the pharmacokinetics, pharmacodynamics, and safety of dotinurad according to the type of hyperuric
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::10025af628492c39a3a95610cc000d3f
https://doi.org/10.1007/s10157-019-01817-3
Zobrazit plný text záznamu
8
Clinical efficacy and safety of dotinurad, a novel selective urate reabsorption inhibitor, in Japanese hyperuricemic patients with or without gout: an exploratory, randomized, multicenter, double-blind, placebo-controlled, parallel-group early phase 2 study
Autor: Takafumi Sano, Tomomitsu Sasaki, Tatsuo Hosoya, Masahiko Fushimi, Tetsuo Ohashi
Publikováno v: Clinical and Experimental Nephrology
Background Dotinurad, a novel selective urate reabsorption inhibitor (SURI) that has a future potential for the treatment of hyperuricemia, reduces serum uric acid levels by selectively inhibiting urate transporter 1 (URAT1). We evaluated the efficac
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a358d76d01d211d37b8a3061e99fd034
http://europepmc.org/articles/PMC7066315
Zobrazit plný text záznamu
9
Open-label study of long-term administration of dotinurad in Japanese hyperuricemic patients with or without gout
Autor: Tomomitsu Sasaki, Tatsuo Hosoya, Daisuke Okui, Masahiko Fushimi, Tetsuo Ohashi
Publikováno v: Clinical and Experimental Nephrology
Background Dotinurad is a novel selective urate reabsorption inhibitor (SURI) which reduces serum uric acid levels by selectively inhibiting urate transporter 1 (URAT1). This study was intended to verify the efficacy and safety of dotinurad following
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9870c50a5ab17315c0d7321465e0eda6
https://pubmed.ncbi.nlm.nih.gov/31875931
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje